Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Kiniksa Pharmaceuticals International Yönetim
Yönetim kriter kontrolleri 4/4
Kiniksa Pharmaceuticals International's CEO'su Sanj Patel, Jul2015 tarihinde atandı, in görev süresi 9.25 yıldır. in toplam yıllık tazminatı $ 5.30M olup, şirket hissesi ve opsiyonları dahil olmak üzere 16.3% maaş ve 83.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 2.41% ine doğrudan sahiptir ve bu hisseler $ 42.87M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.8 yıl ve 7.8 yıldır.
Anahtar bilgiler
Sanj Patel
İcra Kurulu Başkanı
US$5.3m
Toplam tazminat
| CEO maaş yüzdesi | 16.3% |
| CEO görev süresi | 9.3yrs |
| CEO sahipliği | 2.4% |
| Yönetim ortalama görev süresi | 3.8yrs |
| Yönetim Kurulu ortalama görev süresi | 7.8yrs |
Son yönetim güncellemeleri
Recent updates
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Aug 07
Kiniksa Pharmaceuticals: Improved Outlook For Arcalyst After Q2 Beat
Jul 24Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Share Price Is Matching Sentiment Around Its Revenues
Jun 19Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Apr 25Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape
Apr 24Kiniksa Pharmaceuticals, Ltd. Just Reported A Surprise Profit And Analysts Updated Their Estimates
Mar 01We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn
Feb 28The Market Doesn't Like What It Sees From Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Revenues Yet
Dec 18We're Interested To See How Kiniksa Pharmaceuticals (NASDAQ:KNSA) Uses Its Cash Hoard To Grow
Nov 10Investors Don't See Light At End Of Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Tunnel
Apr 18Investors Shouldn't Be Too Comfortable With Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Robust Earnings
Nov 10Industry Analysts Just Upgraded Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Revenue Forecasts By 27%
Aug 04Kiniksa Pharmaceuticals GAAP EPS of -$0.29 beats by $0.15, revenue of $26.97M misses by $1.58M, reaffirms FY revenue guidance
Aug 03Analysts Are Updating Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Estimates After Its First-Quarter Results
May 05We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Mar 18Kiniksa: Latest Earnings Beat Shows Light At The End Of The Tunnel
Nov 25Is Kiniksa Pharmaceuticals (NASDAQ:KNSA) A Risky Investment?
Nov 04Kiniksa: Unexciting, Slow Growth Stock
Aug 13We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Jul 31Kiniksa outlines development path for mavrilimumab after FDA feedback
Jun 08Kiniksa: A Look At Mavrilimumab
May 03Here's Why We're Not Too Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Situation
Apr 17What Kind Of Investors Own Most Of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)?
Jan 02
CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$10m |
| Mar 31 2024 | n/a | n/a | US$9m |
| Dec 31 2023 | US$5m | US$864k | US$14m |
| Sep 30 2023 | n/a | n/a | -US$7m |
| Jun 30 2023 | n/a | n/a | US$231m |
| Mar 31 2023 | n/a | n/a | US$196m |
| Dec 31 2022 | US$6m | US$835k | US$183m |
| Sep 30 2022 | n/a | n/a | US$143m |
| Jun 30 2022 | n/a | n/a | -US$112m |
| Mar 31 2022 | n/a | n/a | -US$134m |
| Dec 31 2021 | US$7m | US$803k | -US$158m |
| Sep 30 2021 | n/a | n/a | -US$175m |
| Jun 30 2021 | n/a | n/a | -US$189m |
| Mar 31 2021 | n/a | n/a | -US$184m |
| Dec 31 2020 | US$5m | US$780k | -US$161m |
| Sep 30 2020 | n/a | n/a | -US$140m |
| Jun 30 2020 | n/a | n/a | -US$123m |
| Mar 31 2020 | n/a | n/a | -US$122m |
| Dec 31 2019 | US$5m | US$780k | -US$162m |
| Sep 30 2019 | n/a | n/a | -US$173m |
| Jun 30 2019 | n/a | n/a | -US$170m |
| Mar 31 2019 | n/a | n/a | -US$153m |
| Dec 31 2018 | US$7m | US$740k | -US$103m |
| Sep 30 2018 | n/a | n/a | -US$93m |
| Jun 30 2018 | n/a | n/a | -US$85m |
| Mar 31 2018 | n/a | n/a | -US$76m |
| Dec 31 2017 | US$1m | US$700k | -US$65m |
Tazminat ve Piyasa: Sanj 'ın toplam tazminatı ($USD 5.30M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 5.54M ).
Tazminat ve Kazançlar: Sanj 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Sanj Patel (55 yo)
9.3yrs
Görev süresi
US$5,297,067
Tazminat
Mr. Sanj K. Patel has been the Chief Executive Officer of Kiniksa Pharmaceuticals International, plc (formerly known as Kiniksa Pharmaceuticals, Ltd.) since July 2015. Before founding Kiniksa Pharmaceutica...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Chairman of the Board | 9.3yrs | US$5.30m | 2.41% $ 42.9m | |
| Senior VP & COO | 2.8yrs | US$1.75m | 0.16% $ 2.9m | |
| Senior VP & Chief Medical Officer | 8.2yrs | US$1.79m | 0.073% $ 1.3m | |
| Senior VP & CFO | 3.8yrs | Veri yok | 0.032% $ 573.6k | |
| Chief Accounting Officer & Group VP of Finance | 4.7yrs | Veri yok | 0.037% $ 660.7k | |
| Senior Vice President of Technical Operations | 3.8yrs | Veri yok | Veri yok | |
| Senior VP & Chief Compliance Officer | 3.5yrs | Veri yok | Veri yok | |
| SVP, General Counsel & Secretary | 3.8yrs | Veri yok | Veri yok | |
| Executive Vice President of Corporate Affairs | no data | Veri yok | Veri yok | |
| Senior Vice President of Regulatory Affairs | 3.8yrs | Veri yok | Veri yok | |
| Senior VP & Chief Commercial Officer | 2.8yrs | Veri yok | 0.031% $ 543.2k | |
| Chief Business Officer | less than a year | Veri yok | Veri yok |
3.8yrs
Ortalama Görev Süresi
51.5yo
Ortalama Yaş
Deneyimli Yönetim: KNSA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.8 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Chairman of the Board | 9.3yrs | US$5.30m | 2.41% $ 42.9m | |
| Independent Director | 6.7yrs | US$362.66k | 0.013% $ 234.3k | |
| Lead Independent Director | 9yrs | US$411.06k | 0.028% $ 495.8k | |
| Independent Director | 7.8yrs | US$380.36k | 0.013% $ 234.3k | |
| Independent Director | 9yrs | US$372.55k | 0.013% $ 234.3k | |
| Independent Director | 5.6yrs | US$459.75k | 0.018% $ 322.2k | |
| Independent Director | 4.3yrs | US$365.36k | 0.013% $ 234.3k | |
| Independent Director | 9yrs | US$371.96k | 0.0070% $ 125.0k | |
| Chairman of Scientific Advisory Board | no data | Veri yok | 2.08% $ 36.9m | |
| Independent Director | 6.7yrs | US$365.36k | 0.013% $ 234.3k |
7.8yrs
Ortalama Görev Süresi
56yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: KNSA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.8 yıldır).